{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:37:58Z","timestamp":1793111878100,"version":"4.5.0"},"reference-count":200,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.tvjl.2026.106919","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:43:33Z","timestamp":1791319413000},"page":"106919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The canine tumour micro-environment and advances in antitumour therapy in canine melanoma"],"prefix":"10.1016","volume":"320","author":[{"given":"E.","family":"Hindriks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.J.M.","family":"Zandvliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.A.M.","family":"Sijts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Broere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06210","article-title":"Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients","volume":"7","author":"Agarwal","year":"2021","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.tvjl.2026.106919_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1354\/vp.44-6-823","article-title":"Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas","volume":"44","author":"Al-Dissi","year":"2007","journal-title":"Vet. Pathol."},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00262-005-0025-6","article-title":"Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma","volume":"55","author":"Alexander","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.tvjl.2026.106919_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70020","article-title":"NY-ESO-1 antigen: a promising frontier in cancer immunotherapy","volume":"14","author":"Alsalloum","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaad.2018.09.054","article-title":"Predictors of mucosal melanoma survival in a population-based setting","volume":"81","author":"Altieri","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.tvjl.2026.106919_bib6","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/0008-5472.CAN-12-3366","article-title":"Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity","volume":"73","author":"Andersen","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.tvjl.2026.106919_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetimm.2020.110142","article-title":"Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours","volume":"230","author":"Ariyarathna","year":"2020","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib8","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.4049\/jimmunol.172.5.3289","article-title":"Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients","volume":"172","author":"Atanackovic","year":"2004","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/vco.12815","article-title":"A retrospective study of 101 dogs with oral melanoma treated with a weekly or biweekly 6 Gy \u00d7 6 radiotherapy protocol","volume":"20","author":"Baja","year":"2022","journal-title":"Vet. Comp. Oncol."},{"issue":"11","key":"10.1016\/j.tvjl.2026.106919_bib10","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1245\/s10434-013-3089-0","article-title":"Prognosis of acral melanoma: a series of 281 patients","volume":"20","author":"Bello","year":"2013","journal-title":"Ann. Surg. Oncol."},{"issue":"21","key":"10.1016\/j.tvjl.2026.106919_bib11","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1016\/j.vaccine.2005.08.027","article-title":"Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center","volume":"24","author":"Bergman","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib12","first-page":"1284","article-title":"Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial","volume":"9","author":"Bergman","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib13","doi-asserted-by":"crossref","DOI":"10.4142\/jvs.2019.20.e48","article-title":"Autologous hybrid cell fusion vaccine in a spontaneous intermediate model of breast carcinoma","volume":"20","author":"Bird","year":"2019","journal-title":"J. Vet. Sci."},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2460\/javma.245.4.401","article-title":"Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001\u20132012)","volume":"245","author":"Boston","year":"2014","journal-title":"J. Am. Vet. Med. Assoc."},{"issue":"8","key":"10.1016\/j.tvjl.2026.106919_bib15","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/ani14081224","article-title":"Tumor immune microenvironment and its clinicopathological and prognostic associations in canine splenic hemangiosarcoma","volume":"14","author":"Brachelente","year":"2024","journal-title":"Animals"},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib16","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tvjl.2026.106919_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetimm.2023.110691","article-title":"Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs","volume":"267","author":"Burton","year":"2024","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"7791","key":"10.1016\/j.tvjl.2026.106919_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01652176.2025.2473717","article-title":"Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols","volume":"45","author":"Camerino","year":"2025","journal-title":"Vet. Q."},{"key":"10.1016\/j.tvjl.2026.106919_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetimm.2016.06.006","article-title":"Intratumoral FoxP3 expression is associated with angiogenesis and prognosis in malignant canine mammary tumors","volume":"178","author":"Carvalho","year":"2016","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.tvjl.2026.106919_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetimm.2020.110169","article-title":"Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate","volume":"232","author":"Cascio","year":"2021","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1-2","key":"10.1016\/j.tvjl.2026.106919_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vetimm.2013.01.012","article-title":"Expression of MAGE-A restricted to testis and ovary or to various cancers in dogs","volume":"153","author":"Chen","year":"2013","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"6","key":"10.1016\/j.tvjl.2026.106919_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1354\/vp.40-6-713","article-title":"Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas","volume":"40","author":"Choi","year":"2003","journal-title":"Vet. Pathol."},{"issue":"7","key":"10.1016\/j.tvjl.2026.106919_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235518","article-title":"Development of canine PD-1\/PD-L1 specific monoclonal antibodies and amplification of canine T cell function","volume":"15","author":"Choi","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib25","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/vco.12294","article-title":"PD-1 expression by canine T cells and functional effects of PD-1 blockade","volume":"15","author":"Coy","year":"2017","journal-title":"Vet. Comp. Oncol."},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib26","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.21873\/anticanres.13275","article-title":"Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model","volume":"39","author":"Crossley","year":"2019","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.tvjl.2026.106919_bib27","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","article-title":"A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients","volume":"7","author":"Cursons","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.tvjl.2026.106919_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188738","article-title":"Development of effective tumor immunotherapy using a novel dendritic cell\u2013targeting Toll-like receptor ligand","volume":"12","author":"De Silva","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/vetsci6010003","article-title":"Deregulation of VEGFR-2 and PDGFR expression and microvascular density in a triple-negative model of canine malignant mammary tumors with lymph node or lung metastasis","volume":"6","author":"Dos Anjos","year":"2019","journal-title":"Vet. Sci."},{"issue":"11","key":"10.1016\/j.tvjl.2026.106919_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101205","article-title":"Vaccine-induced ErbB (EGFR\/HER2)-specific immunity in spontaneous canine cancer","volume":"14","author":"Doyle","year":"2021","journal-title":"Transl. Oncol."},{"issue":"5594","key":"10.1016\/j.tvjl.2026.106919_bib31","first-page":"850","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science (1979)"},{"key":"10.1016\/j.tvjl.2026.106919_bib32","unstructured":"European Medicines Agency. Oncept melanoma: Withdrawal of the marketing authorisation application. February 24, 2015. Accessed September 5, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/oncept-melanoma."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CMR.0000000000000352","article-title":"M1 and M2 macrophages\u2019 clinicopathological significance in cutaneous melanoma","volume":"27","author":"Falleni","year":"2017","journal-title":"Melanoma Res."},{"key":"10.1016\/j.tvjl.2026.106919_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-065X.2006.00438.x","article-title":"The testis in immune privilege","volume":"213","author":"Fijak","year":"2006","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.tvjl.2026.106919_bib35","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/cgt.2012.72","article-title":"Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up","volume":"19","author":"Finocchiaro","year":"2012","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib36","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jvim.15852","article-title":"Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma","volume":"34","author":"Flesner","year":"2020","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.tvjl.2026.106919_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.rvsc.2025.105673","article-title":"Cancer registration in dogs and cats: a narrative review of history, current status, and standardization efforts","volume":"191","author":"Fonti","year":"2025","journal-title":"Res. Vet. Sci."},{"key":"10.1016\/j.tvjl.2026.106919_bib38","first-page":"97","article-title":"Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer","volume":"8","author":"Foskett","year":"2017","journal-title":"Vet. Med."},{"issue":"7","key":"10.1016\/j.tvjl.2026.106919_bib39","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.tvjl.2026.106919_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tvjl.2026.106919_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.888411","article-title":"Association of systemic inflammatory and immune indices with survival in canine patients with oral melanoma, treated with experimental immunotherapy alone or experimental immunotherapy plus metronomic chemotherapy","volume":"9","author":"Garcia","year":"2022","journal-title":"Front. Vet. Sci."},{"issue":"12","key":"10.1016\/j.tvjl.2026.106919_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32433","article-title":"Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: a systematic review and meta-analysis","volume":"10","author":"Garutti","year":"2024","journal-title":"Heliyon"},{"issue":"11","key":"10.1016\/j.tvjl.2026.106919_bib43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/vetsci9110628","article-title":"Does TLS exist in canine mammary gland tumours? Preliminary results in simple carcinomas","volume":"9","author":"Giambrone","year":"2022","journal-title":"Vet. Sci."},{"issue":"10","key":"10.1016\/j.tvjl.2026.106919_bib44","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8+ T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/pcmr.12170","article-title":"Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas","volume":"27","author":"Gillard","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/jsap.13111","article-title":"Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma","volume":"61","author":"Giuliano","year":"2020","journal-title":"J. Small Anim. Pract."},{"key":"10.1016\/j.tvjl.2026.106919_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7142375","article-title":"Pilot acute safety evaluation of InnocellTM cancer immunotherapy in canine subjects","volume":"2020","author":"Goodrich","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033274","article-title":"Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer","volume":"7","author":"Goulart","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.tvjl.2026.106919_bib49","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/jsap.12480","article-title":"Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours","volume":"57","author":"Grant","year":"2016","journal-title":"J. Small Anim. Pract."},{"issue":"12","key":"10.1016\/j.tvjl.2026.106919_bib50","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2460\/ajvr.72.12.1631","article-title":"Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor","volume":"72","author":"Grosenbaugh","year":"2011","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.tvjl.2026.106919_bib51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.rvsc.2021.05.009","article-title":"Immunohistochemical expression and prognostic significance of MAGE-A in canine oral malignant melanoma","volume":"137","author":"Guill\u00e9n","year":"2021","journal-title":"Res. Vet. Sci."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib52","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41598-022-06203-w","article-title":"Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages","volume":"12","author":"Gulay","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib53","first-page":"56","article-title":"Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen","volume":"19","author":"Gyorffy","year":"2005","journal-title":"J. Vet. Intern. Med."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"7791","key":"10.1016\/j.tvjl.2026.106919_bib55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.tvjl.2026.106919_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007589","article-title":"Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis","volume":"14","author":"Hendricks","year":"2018","journal-title":"PLoS Genet."},{"issue":"8","key":"10.1016\/j.tvjl.2026.106919_bib57","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.7150\/thno.55760","article-title":"Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?","volume":"11","author":"Hern\u00e1ndez","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib58","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00262-007-0353-9","article-title":"Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma","volume":"57","author":"Hillen","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tvjl.2026.106919_bib59","doi-asserted-by":"crossref","first-page":"110946","DOI":"10.1016\/j.vetimm.2025.110946","article-title":"Cancer-testis antigen expression in canine melanoma and healthy tissues","volume":"284","author":"Hindriks","year":"2025","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/vco.70029","article-title":"Evaluating VEGFR2 as a Target for Anti\u2010Tumour Therapy in Canine Melanoma","volume":"24","author":"Hindriks","year":"2026","journal-title":"Vet. Comp. Oncol."},{"issue":"11","key":"10.1016\/j.tvjl.2026.106919_bib61","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1348-0421.2009.00194.x","article-title":"Relationship between regulatory and type 1 T cells in dogs with oral malignant melanoma","volume":"54","author":"Horiuchi","year":"2010","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.tvjl.2026.106919_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetimm.2019.109912","article-title":"Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy","volume":"216","author":"Hutchison","year":"2019","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib64","doi-asserted-by":"crossref","DOI":"10.4142\/jvs.23144","article-title":"Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors","volume":"25","author":"Igase","year":"2024","journal-title":"J. Vet. Sci."},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib65","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/vco.12829","article-title":"Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: a follow-up case report","volume":"20","author":"Igase","year":"2022","journal-title":"Vet. Comp. Oncol."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75533-4","article-title":"A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs","volume":"10","author":"Igase","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tvjl.2026.106919_bib67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vetimm.2017.07.001","article-title":"Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma","volume":"190","author":"Inoue","year":"2017","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib68","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/biom13020348","article-title":"Natural killer T and natural killer cell-based immunotherapy strategies targeting cancer","volume":"13","author":"Iyoda","year":"2023","journal-title":"Biomolecules"},{"issue":"20","key":"10.1016\/j.tvjl.2026.106919_bib69","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2008.19.9919","article-title":"Macrophage markers in serum and tumor have prognostic impact in American joint committee on cancer stage I\/II melanoma","volume":"27","author":"Jensen","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.tvjl.2026.106919_bib70","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00262-007-0282-7","article-title":"Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma","volume":"56","author":"Kamstock","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib71","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib72","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00002371-199807000-00001","article-title":"The use of melanosomal proteins in the immunotherapy of melanoma","volume":"21","author":"Kawakami","year":"1998","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.tvjl.2026.106919_bib73","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/03009858241273318","article-title":"Evaluation of SOX-10 immunohistochemical expression in canine melanoma and non-melanocytic tumors by tissue microarray","volume":"61","author":"King","year":"2024","journal-title":"Vet. Pathol."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib74","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41598-021-81330-4","article-title":"Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600 E\/K mutated malignant melanomas","volume":"11","author":"Klein","year":"2021","journal-title":"Sci. Rep."},{"issue":"9-10","key":"10.1016\/j.tvjl.2026.106919_bib75","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41417-019-0080-3","article-title":"Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma","volume":"26","author":"Konduri","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.tvjl.2026.106919_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601773","article-title":"Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling","volume":"16","author":"Kraja","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib77","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/03009858211023946","article-title":"Immunohistochemical evaluation of immune cell infiltration in canine gliomas","volume":"58","author":"Krane","year":"2021","journal-title":"Vet. Pathol."},{"issue":"19","key":"10.1016\/j.tvjl.2026.106919_bib78","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib79","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.tvjl.2026.106919_bib80","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00262-018-2201-5","article-title":"Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma","volume":"67","author":"Kurupati","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.tvjl.2026.106919_bib81","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00262-011-1071-x","article-title":"Prognostic impact of B-cell density in cutaneous melanoma","volume":"60","author":"Lad\u00e1nyi","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1537581","article-title":"Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients","volume":"8","author":"Lee","year":"2019","journal-title":"Oncoimmunology"},{"issue":"14","key":"10.1016\/j.tvjl.2026.106919_bib83","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/pros.24199","article-title":"CE. Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer","volume":"81","author":"Leis-Filho","year":"2021","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib84","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00262-021-03033-z","article-title":"Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma","volume":"71","author":"Lenz","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib85","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12917-021-03026-1","article-title":"Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models","volume":"17","author":"Li","year":"2021","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.tvjl.2026.106919_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1691608","article-title":"Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment","volume":"16","author":"Liang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tvjl.2026.106919_bib87","first-page":"8","article-title":"Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma","volume":"6","author":"Liao","year":"2006","journal-title":"Cancer Immun."},{"issue":"8","key":"10.1016\/j.tvjl.2026.106919_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160485","article-title":"PD-1 antibody monotherapy for malignant melanoma: a systematic review and meta-analysis","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.tvjl.2026.106919_bib89","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-16-2152","article-title":"KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells","volume":"23","author":"London","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.tvjl.2026.106919_bib90","first-page":"2755","article-title":"Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies","volume":"9","author":"London","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.tvjl.2026.106919_bib91","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib92","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12917-020-02675-y","article-title":"Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study","volume":"16","author":"Lucroy","year":"2020","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.tvjl.2026.106919_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291727","article-title":"Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours","volume":"18","author":"Maekawa","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.tvjl.2026.106919_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098415","article-title":"Expression of PD-L1 on canine tumor cells and enhancement of IFN-\u03b3 production from tumor-infiltrating cells by PD-L1 blockade","volume":"9","author":"Maekawa","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib95","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-021-00147-6","article-title":"PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma","volume":"5","author":"Maekawa","year":"2021","journal-title":"NPJ Precis Oncol."},{"issue":"6","key":"10.1016\/j.tvjl.2026.106919_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157176","article-title":"Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma","volume":"11","author":"Maekawa","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib97","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1038\/s41598-017-09444-2","article-title":"A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma","volume":"7","author":"Maekawa","year":"2017","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.tvjl.2026.106919_bib98","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":"Determinants of BRAF mutations in primary melanomas","volume":"95","author":"Maldonado","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1939-1676.2010.0627.x","article-title":"Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs","volume":"25","author":"Manley","year":"2011","journal-title":"J. Vet. Intern. Med."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00325-3","article-title":"Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients","volume":"11","author":"Marable","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib101","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s40425-019-0624-y","article-title":"Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers","volume":"7","author":"Marconato","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib102","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/cancers14051347","article-title":"A target animal effectiveness study on adjuvant peptide-based vaccination in dogs with non-metastatic appendicular osteosarcoma undergoing amputation and chemotherapy","volume":"14","author":"Marconato","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib103","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/cancers12051272","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma: Preliminary toxicity and activity data in dogs","volume":"12","author":"Marconato","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.tvjl.2026.106919_bib104","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.3390\/cancers15174209","article-title":"A phase 2, single-arm, open-label clinical trial on adjuvant peptide-based vaccination in dogs with aggressive hemangiosarcoma undergoing surgery and chemotherapy","volume":"15","author":"Marconato","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib105","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.2004638","article-title":"Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors","volume":"13","author":"Mason","year":"2021","journal-title":"MAbs"},{"issue":"17","key":"10.1016\/j.tvjl.2026.106919_bib106","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-16-0088","article-title":"Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma","volume":"22","author":"Mason","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib107","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.tvjl.2011.02.020","article-title":"Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma","volume":"190","author":"Mayayo","year":"2011","journal-title":"Vet. J."},{"issue":"10","key":"10.1016\/j.tvjl.2026.106919_bib108","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.4049\/jimmunol.0801898","article-title":"Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies","volume":"182","author":"Michaeli","year":"2009","journal-title":"J. Immunol."},{"issue":"18","key":"10.1016\/j.tvjl.2026.106919_bib109","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.1158\/0008-5472.CAN-10-0600","article-title":"IFN\u03b3 markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models","volume":"70","author":"Mito","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.tvjl.2026.106919_bib110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tvjl.2018.02.016","article-title":"Tumour-associated macrophages: relation with progression and invasiveness, and assessment of M1\/M2 macrophages in canine mammary tumours","volume":"234","author":"Monteiro","year":"2018","journal-title":"Vet. J."},{"issue":"10","key":"10.1016\/j.tvjl.2026.106919_bib111","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd.2018.165","article-title":"Burgeoning oncology pipeline raises questions about sustainability","volume":"17","author":"Moser","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tvjl.2026.106919_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2022.105833","article-title":"Standardized approach for evaluating tumor infiltrating lymphocytes in canine mammary carcinoma: spatial distribution and score as relevant features of tumor malignancy","volume":"283-284","author":"Muscatello","year":"2022","journal-title":"Vet. J."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib113","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/vco.12642","article-title":"Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector","volume":"19","author":"Musser","year":"2021","journal-title":"Vet. Comp. Oncol."},{"issue":"9","key":"10.1016\/j.tvjl.2026.106919_bib114","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.4049\/jimmunol.1001323","article-title":"CD20+ B cells: the other tumor-infiltrating lymphocytes","volume":"185","author":"Nelson","year":"2010","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/vco.12475","article-title":"Cancer-testis antigens in canine histiocytic sarcoma and other malignancies","volume":"17","author":"Nemec","year":"2019","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.tvjl.2026.106919_bib116","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vetimm.2018.02.007","article-title":"Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1","volume":"198","author":"Nemoto","year":"2018","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100930","article-title":"NK cell infiltration is associated with improved overall survival in solid cancers: a systematic review and meta-analysis","volume":"14","author":"Nersesian","year":"2021","journal-title":"Transl. Oncol."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cancers11020137","article-title":"Treatment combining CD200 immune checkpoint inhibitor and tumor-lysate vaccination after surgery for pet dogs with high-grade glioma","volume":"11","author":"Olin","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib119","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/vco.12057","article-title":"A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma","volume":"11","author":"Ottnod","year":"2013","journal-title":"Vet. Comp. Oncol."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib120","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1676615","article-title":"Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma","volume":"9","author":"Panjwani","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tvjl.2026.106919_bib121","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.rvsc.2021.02.007","article-title":"M1 and M2 tumour-associated macrophages subsets in canine malignant mammary tumours: An immunohistochemical study","volume":"136","author":"Parisi","year":"2021","journal-title":"Res. Vet. Sci."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib122","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib123","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/2326-6066.CIR-19-0545","article-title":"Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma","volume":"8","author":"Pavlick","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib124","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp100219n","article-title":"Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data","volume":"8","author":"Pesonen","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tvjl.2026.106919_bib125","unstructured":"Phillips C. National Cancer Institute at the National Institutes of Health. Experimental mRNA vaccine hints at potential against glioblastoma. June 11, 2024. Accessed October 3, 2025. http:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2024\/glioblastoma-mrna-vaccine-layered-nanoparticle."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib126","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/vco.12239","article-title":"Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination","volume":"15","author":"Piras","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.tvjl.2026.106919_bib127","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.critrevonc.2017.05.001","article-title":"Melanoma antigens and related immunological markers","volume":"115","author":"Pitcovski","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tvjl.2026.106919_bib128","article-title":"Melanoma of the dog and cat: consensus and guidelines","volume":"11","author":"Polton","year":"2024","journal-title":"Front. Vet. Sci."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0300985820960131","article-title":"FoxP3, CTLA-4, and IDO in canine melanocytic tumors","volume":"58","author":"Porcellato","year":"2021","journal-title":"Vet. Pathol."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0300985818808530","article-title":"FoxP3 and IDO in canine melanocytic tumors","volume":"56","author":"Porcellato","year":"2019","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.tvjl.2026.106919_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.878949","article-title":"Tumour-associated macrophages in canine oral and cutaneous melanomas and melanocytomas: Phenotypic and prognostic assessment","volume":"9","author":"Porcellato","year":"2022","journal-title":"Front. Vet. Sci."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib132","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/vco.12556","article-title":"Tumour-infiltrating lymphocytes in canine melanocytic tumours: an investigation on the prognostic role of CD3+ and CD20+ lymphocytic populations","volume":"18","author":"Porcellato","year":"2020","journal-title":"Vet. Comp. Oncol."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib133","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.tvjl.2026.106919_bib134","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1158\/2159-8290.CD-24-1208","article-title":"Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype","volume":"15","author":"Pozniak","year":"2025","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.tvjl.2026.106919_bib135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1354\/vp.37-6-597","article-title":"Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases","volume":"37","author":"Ramos-Vara","year":"2000","journal-title":"Vet. Pathol."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib136","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0300985810382095","article-title":"Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with melan A","volume":"48","author":"Ramos-Vara","year":"2011","journal-title":"Vet. Pathol."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib137","first-page":"819","article-title":"Localization of integrin \u03b1v\u03b23 and vascular endothelial growth factor receptor-2 (KDR\/Flk-1) in cutaneous and oral melanomas of dog","volume":"18","author":"Rawlings","year":"2003","journal-title":"Histol. Histopathol."},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib138","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007963","article-title":"Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer","volume":"12","author":"Razmara","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tvjl.2026.106919_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1646849","article-title":"Comparative transcriptomic analysis of tumor-infiltrating canine natural killer cells and candidate biomarkers from first-in-dog NK immunotherapy trials","volume":"16","author":"Razmara","year":"2025","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.tvjl.2026.106919_bib140","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-13-3042","article-title":"CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA","volume":"20","author":"Riccardo","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004007","article-title":"Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial","volume":"10","author":"Riccardo","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tvjl.2026.106919_bib142","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919855491","article-title":"Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma","volume":"11","author":"Riccardo","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"12","key":"10.1016\/j.tvjl.2026.106919_bib143","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/vetsci11120628","article-title":"APAVAC immunotherapy for the adjuvant treatment of a canine mucosal melanoma","volume":"11","author":"Rinaldi","year":"2024","journal-title":"Vet. Sci."},{"issue":"22","key":"10.1016\/j.tvjl.2026.106919_bib144","doi-asserted-by":"crossref","first-page":"8770","DOI":"10.1158\/0008-5472.CAN-09-1725","article-title":"Mammary tumor development in dogs is associated with BRCA1 and BRCA2","volume":"69","author":"Rivera","year":"2009","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.tvjl.2026.106919_bib145","article-title":"Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients","volume":"4","author":"Rotolo","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib146","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/vco.13020","article-title":"Lymphoid aggregates in canine cutaneous and subcutaneous sarcomas: Immunohistochemical and gene expression evidence for tertiary lymphoid structures","volume":"23","author":"Rugh","year":"2025","journal-title":"Vet. Comp. Oncol."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib147","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/vco.12383","article-title":"Association of tumour-infiltrating regulatory T cells with adverse outcomes in dogs with malignant tumours","volume":"16","author":"Sakai","year":"2018","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.tvjl.2026.106919_bib148","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2018.04.009","article-title":"MAGE-A antigens as targets for cancer immunotherapy","volume":"67","author":"Schooten","year":"2018","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib149","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41388-018-0444-4","article-title":"Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma","volume":"38","author":"Shao","year":"2019","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.tvjl.2026.106919_bib150","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-Current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib151","first-page":"195","article-title":"Programmed cell death ligand 1 expression in canine cancer","volume":"30","author":"Shosu","year":"2016","journal-title":"In Vivo (Brooklyn)"},{"issue":"7","key":"10.1016\/j.tvjl.2026.106919_bib152","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1535-7163.MCT-13-0288","article-title":"Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients","volume":"13","author":"Singer","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib153","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0300985810387447","article-title":"Immunohistochemical diagnosis of canine oral amelanotic melanocytic neoplasms","volume":"48","author":"Smedley","year":"2011","journal-title":"Vet. Pathol."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056912","article-title":"Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53","volume":"8","author":"Soong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tvjl.2026.106919_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2021.772932","article-title":"T cell immune profiles of blood and tumor in dogs diagnosed with malignant melanoma","volume":"8","author":"Sparger","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.tvjl.2026.106919_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2024.106196","article-title":"Prospective study of successful autologous dendritic cell therapy in dogs with splenic stage II hemangiosarcoma","volume":"306","author":"Spiller","year":"2024","journal-title":"Vet. J."},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib157","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib158","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/vetsci7030109","article-title":"A preliminary study of the cross-reactivity of canine MAGE-A with hominid monoclonal antibody 6C1 in canine mammary gland tumors: an attractive target for cancer diagnostic, prognostic and immunotherapeutic development in dogs","volume":"7","author":"Srisawat","year":"2020","journal-title":"Vet. Sci."},{"key":"10.1016\/j.tvjl.2026.106919_bib159","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43856-022-00082-y","article-title":"Long-term relative survival in uveal melanoma: a systematic review and meta-analysis","volume":"2","author":"St\u00e5lhammar","year":"2022","journal-title":"Commun. Med."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamadermatol.2022.4959","article-title":"Association between metastatic melanoma response to checkpoint inhibitor therapy and tumor-infiltrating lymphocyte classification on primary cutaneous melanoma biopsies","volume":"159","author":"Stephens","year":"2023","journal-title":"JAMA Dermatol."},{"issue":"4","key":"10.1016\/j.tvjl.2026.106919_bib161","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/03009858211011939","article-title":"PD-1, PD-L1, and PD-L2 gene expression and tumor infiltrating lymphocytes in canine melanoma","volume":"58","author":"Stevenson","year":"2021","journal-title":"Vet. Pathol."},{"issue":"8","key":"10.1016\/j.tvjl.2026.106919_bib162","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1245\/s10434-022-11478-4","article-title":"Prognostic significance of primary tumor-infiltrating lymphocytes in a contemporary melanoma cohort","volume":"29","author":"Straker","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"2-3","key":"10.1016\/j.tvjl.2026.106919_bib163","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1053\/jcpa.2002.0576","article-title":"Immunohistochemical detection of melanoma-specific antigens in spontaneous canine melanoma","volume":"127","author":"Sulaimon","year":"2002","journal-title":"J. Comp. Pathol."},{"issue":"7","key":"10.1016\/j.tvjl.2026.106919_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201222","article-title":"Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma","volume":"13","author":"Tagawa","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib165","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.tvjl.2006.11.005","article-title":"Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells","volume":"175","author":"Tamura","year":"2008","journal-title":"Vet. J."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib166","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12917-021-02864-3","article-title":"A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: A case report and in vitro analysis","volume":"17","author":"Tani","year":"2021","journal-title":"BMC Vet. Res."},{"issue":"22","key":"10.1016\/j.tvjl.2026.106919_bib167","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/cncr.31734","article-title":"NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma","volume":"124","author":"Tarhini","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.tvjl.2026.106919_bib168","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.ymthe.2023.06.004","article-title":"A chimeric human\/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma","volume":"31","author":"Tarone","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tvjl.2026.106919_bib169","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3389\/fonc.2020.01642","article-title":"Receptor tyrosine kinases in osteosarcoma treatment: Which is the key target?","volume":"10","author":"Tian","year":"2020","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib170","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1292\/jvms.15-0510","article-title":"A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma","volume":"78","author":"Treggiari","year":"2016","journal-title":"J. Vet. Med. Sci."},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib171","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/2326-6066.CIR-13-0089","article-title":"Effect of Montanide and poly-ICLC adjuvant on human self\/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial","volume":"1","author":"Tsuji","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib172","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1939-1676.2007.tb02936.x","article-title":"Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma","volume":"21","author":"U\u2019Ren","year":"2007","journal-title":"J. Vet. Intern. Med."},{"issue":"9","key":"10.1016\/j.tvjl.2026.106919_bib173","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tvjl.2026.106919_bib174","unstructured":"University of Florida Health. Canine RNA-nanoparticle vaccine combined with anti-PD1 drug against osteosarcoma for canine Ppatients (currently enrolling). Accessed October 3, 2025. https:\/\/research.vetmed.ufl.edu\/research-programs\/clinical-trials\/small-animal\/mrna-vaccine-study-for-dogs-with-appendicular-osteosarcoma-currently-enrolling\/#:~:text=Research%20Programs%20Overview-,Canine%20RNA%2DNanoparticle%20Vaccine%20Combined%20with%20Anti%2DPD1%20Drug%20Against,Enrollment%20Status:%20Currently%20Enrolling."},{"key":"10.1016\/j.tvjl.2026.106919_bib175","unstructured":"U.S. Department of Agriculture (USDA). Summary of studies supporting USDA product licensure: Canine melanoma vaccine. October 26, 2009. Accessed September 5, 2025. http:\/\/www.aphis.usda.gov\/aphis\/ourfocus\/animalhealth\/veterinary-biologics\/product-summaries\/vet-label-data\/b00ab055-e956-42d4-814e-5a13fcf0b0ae."},{"key":"10.1016\/j.tvjl.2026.106919_bib176","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2164-10-135","article-title":"Comparative expression pathway analysis of human and canine mammary tumors","volume":"10","author":"Uva","year":"2009","journal-title":"BMC Genomics"},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib177","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jsap.12613","article-title":"Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK","volume":"58","author":"Verganti","year":"2017","journal-title":"J. Small Anim. Pract."},{"issue":"10","key":"10.1016\/j.tvjl.2026.106919_bib178","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1517\/14728222.2015.1068759","article-title":"Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors","volume":"19","author":"Wang","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10427","key":"10.1016\/j.tvjl.2026.106919_bib179","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.tvjl.2026.106919_bib180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/2326-6066.CIR-13-0157","article-title":"Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines","volume":"2","author":"Weir","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib181","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1740-8261.2004.04045.x","article-title":"Preliminary study of plasma vascular endothelial growth factor (VEGF) during low- and high-dose radiation therapy of dogs with spontaneous tumors","volume":"45","author":"Wergin","year":"2004","journal-title":"Vet. Radiol. Ultrasound."},{"key":"10.1016\/j.tvjl.2026.106919_bib182","first-page":"15","article-title":"Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours","volume":"18","author":"Wergin","year":"2004","journal-title":"In Vivo (Brooklyn)"},{"issue":"6","key":"10.1016\/j.tvjl.2026.106919_bib183","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0b013e31829d8a1b","article-title":"Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma","volume":"36","author":"Westberg","year":"2013","journal-title":"J. Immunother."},{"issue":"2","key":"10.1016\/j.tvjl.2026.106919_bib184","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"issue":"8","key":"10.1016\/j.tvjl.2026.106919_bib185","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-18-2652","article-title":"Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma","volume":"25","author":"Wong","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib186","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1111\/vco.12332","article-title":"Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: a phase I dose finding study","volume":"16","author":"Wouda","year":"2018","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.tvjl.2026.106919_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1028647","article-title":"The role of angiogenesis in melanoma: Clinical treatments and future expectations","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tvjl.2026.106919_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2024.1397518","article-title":"Immunotherapeutic allogeneic dendritic cell and autologous tumor cell fusion vaccine alone or combined with radiotherapy in canine oral malignant melanoma is safe and potentially effective","volume":"11","author":"Xia","year":"2024","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.tvjl.2026.106919_bib189","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.20.00902","article-title":"Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma","volume":"39","author":"Yan","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.tvjl.2026.106919_bib190","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-18-0720","article-title":"Genomic features of exceptional response in vemurafenib cobimetinib\u2013treated patients with BRAFV600-mutated metastatic melanoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tvjl.2026.106919_bib191","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.vetimm.2016.10.011","article-title":"Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs","volume":"182","author":"Yannelli","year":"2016","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"3","key":"10.1016\/j.tvjl.2026.106919_bib192","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/0300985821999321","article-title":"Intratumoral T-lymphocyte subsets in canine oral melanoma and their association with clinical and histopathological parameters","volume":"58","author":"Yasumaru","year":"2021","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.tvjl.2026.106919_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2023.105992","article-title":"CD204+ tumor-associated macrophages are associated with clinical outcome in canine pulmonary adenocarcinoma and transitional cell carcinoma","volume":"296-297","author":"Yokota","year":"2023","journal-title":"Vet. J."},{"key":"10.1016\/j.tvjl.2026.106919_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetimm.2024.110716","article-title":"Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma","volume":"269","author":"Yokota","year":"2024","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1","key":"10.1016\/j.tvjl.2026.106919_bib195","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2287250","article-title":"Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors","volume":"15","author":"Yoshimoto","year":"2023","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.tvjl.2026.106919_bib196","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tvjl.2026.106919_bib197","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/CMAR.S520937","article-title":"Real-world efficacy and safety of anti-PD-1 antibody plus apatinib and temozolomide for advanced acral melanoma","volume":"17","author":"Zhang","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.tvjl.2026.106919_bib198","article-title":"Neoantigen: a new breakthrough in tumor immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.tvjl.2026.106919_bib199","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008611","article-title":"Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma","volume":"12","author":"Zhao","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tvjl.2026.106919_bib200","article-title":"New insights into the role of macrophages in cancer immunotherapy","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109002332600376X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109002332600376X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:12:00Z","timestamp":1793110320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109002332600376X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":200,"alternative-id":["S109002332600376X"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2026.106919","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The canine tumour micro-environment and advances in antitumour therapy in canine melanoma","name":"articletitle","label":"Article Title"},{"value":"The Veterinary Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvjl.2026.106919","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106919"}}